, Bienzle U, Vonk R and Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of HBV, HCV, and HIV infection among injecting drug users in Berlin. International Journal of Epidemiology 1997; 26: 1359-1366. Background. Injecting drug users (IDU) are at risk of parenterally transmitted diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infection. We investigated whether a history of syringe sharing in prison is a risk factor for these infections. In the longitudinal part of the study, HBV, HCV, and HIV seroincidence rates were determined. Methods. The participants were recruited by multisite-sampling at different agencies for IDU. Data on risk behaviour were obtained by a standardized questionnaire. Serological markers for HBV, HCV, and HIV were determined. Logistic regression analysis was performed to adjust for confounding effects. Results. A history of syringe sharing in prison was significantly associated with HBV (adjusted prevalence odds ratio [POR] = 3.9, 95% confidence interval [CI] : 2-10), HCV (POR = 9.7, 95% CI : 3-33), and HIV infection (POR = 10.4, 95% CI : 4-29). The HIV seroincidence rate was 5.9 per 100 person-years. None of the IDU receiving methadone maintenance treatment (MMT) seroconverted whereas the HIV incidence was 8.5 among IDU not in MMT (P = 0.01). Conclusions. The increased risk of HBV, HCV, and HIV infection among IDU who had shared syringes in prison warrants specific preventive action. The longitudinal data suggest that IDU in MMT have a lower risk of HIV infection.
Injecting drug users (IDU) are at high risk of acquiring parenterally transmitted diseases. For human immunodeficiency (HIV) infection a variety of more specific risk factors have been identified such as needle sharing, use of shooting galleries, cocaine use, or number of drug-injecting sex partners. [1] [2] [3] [4] [5] [6] [7] More recently, studies provided evidence that imprisonment, and more specifically syringe sharing in prison may be an important risk factor for HIV infection. [8] [9] [10] [11] [12] The prevention of hepatitis B and C virus (HBV, HCV) infections is also of major public health concern because infected individuals carry a substantial risk of chronic liver disease of 5 to 10% (HBV), and of more than 50% (HCV). Moreover, individuals infected with HBV, and to a lesser degree those with HCV infection, may transmit the virus to their sexual partners, and in case of females to their offspring. [13] [14] [15] It is important to identify specific risk factors for HBV and HCV infection among IDU in order to implement appropriate prevention measures. Data on possible associations between risk behaviour in prison, and HBV or HCV infection, however, are scarce.
Only a few longitudinal studies have been carried out on HIV, HBV, and HCV transmission among larger cohorts of IDU (Northern Italy, Amsterdam, Baltimore, New York City). [16] [17] [18] [19] [20] [21] The HIV incidence rates varied between 3 and 9 per 100 person-years. Higher HIV incidence rates were found among new drug injectors, and among those who have recently shared syringes. 16, 17 In Berlin, a range of prevention measures for IDU have been implemented since the mid-1980s including syringe exchange programmes, syringe vending machines, and increased outreach efforts. Since 1988, access to methadone maintenance treatment (MMT) has been improved in particular for IDU with serious health problems, and those with a long history of injecting drugs. Cross-sectional studies showed lower levels of current syringe sharing (i.e. injecting by syringes/ needles which had already been used by another IDU) among IDU in MMT. 22 However, no data are available on HIV seroconversion rates among IDU in Germany, and on possible risk factors for or protective factors against seroconversion.
METHODS

Study Population and Data Collection
In 1993 and 1994, a study was carried out in order to investigate the epidemiology of viral hepatitis B and C, and HIV infection among IDU in Berlin. The participants were recruited at different agencies and services for IDU to obtain a sample as representative as possible. The sites of recruitment included three therapeutic communities for long-term drug-free treatment with different thresholds of access, and the two storefront agencies in Berlin, which provide syringe exchange, counselling, and basic medical care. These agencies are situated close to the main gathering places of IDU. The IDU were not sampled directly on the streets because it would not have been feasible to draw blood there for laboratory tests. The IDU were eligible for the study if they had injected drugs in the previous 3 months. Participation in the study was voluntary, and verbal informed consent was obtained. The participants received an incentive of DM 20. The response rates among all eligible clients of the recruitment sites during the study period were 86% at the treatment centres, and 84% at the storefront agencies, respectively. All participants were interviewed by trained interviewers using a standardized questionnaire. The questionnaire covered sociodemographic and behavioural characteristics, and detailed injection and sexual risk practices. The question on the relevant injection risk behaviour was phrased as follows: 'How often did you inject drugs with needles and/or syringes that have already been injected with by other people?'. For simplicity reasons this behaviour is referred to as 'syringe sharing' throughout the paper. Another central topic of the questionnaire referred to risk behaviour during periods of imprisonment. The participants were asked if they had been imprisoned since the time they started to inject drugs, and if so, how often they had injected drugs, and how often they had shared syringes while in prison. The responses on imprisonment were crosschecked with clients' records in a subsample of n = 100 in the treatment centres. No inconsistencies between the interviews and the records were found.
Overall, 697 IDU were enrolled in the study (storefront agencies 523, treatment centres 174). Of these IDU, 22 had to be excluded before data analysis because they had been interviewed twice at different agencies, and six IDU were excluded because of inconsistent answers in the questionnaire or indeterminate laboratory results. The sera of the remaining 669 IDU were tested for HIV antibodies. In 94 individuals testing for HBV and HCV seromarkers was not possible (e.g. insufficient volumes of serum). Data analysis was performed on the 575 IDU who had complete testing for HIV, HBV and HCV seromarkers (storefront agencies 418, treatment centres 157).
At one storefront agency a longitudinal study was carried out. A regular outpatient service was set up offering free medical care and testing for HIV infection and hepatitis. All participants of the cross-sectional study recruited at this agency (n = 294) were invited to return every 4-6 months for follow-up investigations (laboratory tests, standardized interviews). On each visit a blood sample was drawn, and data on social and behavioural characteristics were obtained with respect to the previous 6 months, or if the last visit had been less than 6 months ago for the time since that visit. Of the 294 IDU originally recruited at the storefront agency, 191 (65%) individuals were seen at least twice for follow-up visits.
Laboratory Methods
All serum samples were tested for anti-HBc and HBsAg by enzyme-linked immunosorbent assay (ELISA) (Abbott, Wiesbaden, Germany), and for anti-HBs by radioimmunoassay (Abbott). If these seromarkers did not allow an unequivocal diagnosis of the hepatitis B serostatus, further tests for anti-HBc IgM, HBeAg, and anti-HBe were performed by ELISA (Abbott). Individuals were regarded as having been infected by HBV if any of the HBV seromarkers was positive except if they showed positive reactions against anti-HBs which only indicates previous vaccination. Antibodies against HCV were determined by a second generation ELISA (Abbott). In sera showing indeterminate results a RIBA was performed for confirmation. All HIV antibodies were assessed by ELISA (HIV-1/2-ELISA, Sanofi Pasteur, Freiburg, Germany). Confirmatory testing was done by Western blot (Sanofi Pasteur) according to WHO guidelines. 23 
Statistical Methods
Cross-sectional study. To assess the associations between categorical variables (e.g. demographic and behavioural variables such as gender, age group, syringe sharing, imprisonment, prostitution, history of sexually transmitted diseases [STD] ) and the outcome variables HBV, HCV, and HIV infection χ 2 tests or χ 2 tests for trend were performed. Logistic regression analysis was performed to adjust for potential confounding effects on the exposure-outcome associations. All variables which were associated with the respective outcome (P Ͻ 0.1), and variables which were regarded as potential confounders a priori were entered into the model. Variables were kept in the model if they improved the fit of the previous model significantly, i.e. if their inclusion resulted in a significant reduction in the deviance. 24, 25 Possible interactions were also assessed.
Longitudinal study. The HIV, HBV, and HCV seroincidence rates per 100 person-years with 95% confidence intervals (CI) were calculated. In seroconverters, seroconversion was considered to have occurred at midpoint between the date of the last negative and the first positive serological test. Overall HIV incidence rates were calculated for the total group, and for subgroups according to relevant demographic characteristics or behavioural characteristics during the 6-month time periods before the follow-up visits (e.g. gender, age, syringe sharing, sex with IDU, and MMT). To compare HIV incidence rates among different subgroups of IDU the probabilities of the occurrence of the observed numbers of seroconversions in the respective subgroups as compared to the expected numbers were calculated using the binomial distribution.
The data analysis was performed with anonymized data sets.
RESULTS
Characteristics of the Study Population
Of the total study population, 73% were males. The median age was 30 years (interquartile range [26] [27] [28] [29] [30] [31] [32] [33] [34] . The median duration of injecting drug use was 8 years (interquartile range [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The main types of drugs injected during the previous 6 months were: heroin 96%, cocaine 77%, benzodiazepines 35%, barbiturates 14%, and amphetamines 12%.
Of all participants, 75% had ever shared syringes, and 42% had done so in the previous 6 months. A history of incarceration, and of syringe sharing in prison was reported by 67%, and 22% of the IDU, respectively. In the previous 6 months, 20% of all IDU had been imprisoned, and 7% had borrowed used syringes in prison. Of the females, 69% and 11% of the males had engaged in prostitution.
Of all IDU, 62% had serological evidence of HBV infection, and only 5% had serological evidence of HBV vaccination. Thirty-eight (7%) IDU were HBsAgpositive, and 18 of these were also HBeAg-positive.
The HCV, and HIV seroprevalences were 84%, and 15%, respectively.
No seromarkers for any of the three viral infections were found in only 12% of the IDU, whereas 48% were seropositive for two, and 11% for all three infections.
Associations between Behavioural Characteristics, and HBV, HCV, and HIV Exposure (Univariate Analysis)
In univariate analysis, a variety of sociodemographic and behavioural variables were significantly associated with seropositivity for HBV, HCV, and HIV, respectively. Table 1 shows the most relevant associations. The seroprevalences of all three infections increased with age, and with longer history of injecting drugs. It is noteworthy that among the IDU injecting for less than 5 years the HCV and HBV seroprevalences were already as high as 66% and 46%, respectively. The IDU who had shared syringes, who had been imprisoned, and particularly those who had shared syringes while in prison, were more likely to be seropositive for HBV, HCV, and HIV.
Determinants of HBV, HCV, and HIV Infection (Multivariate Analysis)
After adjusting for confounding effects in logistic regression analysis, syringe sharing in prison remained an important determinant of all three viral infections. Compared to those who had never been imprisoned, IDU who had shared syringes in prison more than 50 times had an adjusted HBV prevalence odds ratio (POR) of 3.9 (95% CI : 1.5-10), and an adjusted HIV POR of 10.4 (95% CI : 3.7-29). Syringe sharing in prison was also strongly associated with HCV infection (HCV POR = 9.7, 95% CI : 2.9-33) ( Tables 2, 3 , and 4). Inclusion of the variable 'Syringe sharing outside prison' did not change the adjusted POR significantly nor did it improve the fit of the model. A history of prostitution was an independent determinant of HCV, and of HIV infection, and a history of an STD was independently associated with HBV and HIV infection (Tables 2,  3 , and 4).
HBV, HCV, and HIV Seroincidence Rates
The longitudinal study was carried out at one storefront agency where initially 294 IDU had been recruited for the cross-sectional study. The IDU (n = 191) who returned for follow-up visits as compared to the IDU (n = 103) who could not be followed up after the baseline investigation had injected for a longer time (mean 10.7 versus 9.6 years, P Ͻ 0.05). They were more likely to have been incarcerated (75% versus 61%), to report a previous STD (40% versus 29%), to have injected sedatives in the previous 6 months (37% versus 27%), and to currently receive MMT (29% versus 18%). No differences between participants and nonparticipants were observed with respect to gender, age, frequency of syringe sharing (overall and in prison), and HIV, HBV, and HCV seroprevalence. Of the 191 IDU, 36 (19%) were anti-HIV-positive at baseline. Baseline HBV and HCV serostatus were available from 158, and 153 IDU. The respective HBV and HCV seroprevalences were 64%, and 88%.
There were nine HIV seroconversions resulting in an incidence rate of 5.9 per 100 person-years (95% CI : 2.7-11). The HBV and HCV seroincidence rates were 26.3 (95% CI : 15-43), and 34.3 (95% CI : 13-75), respectively ( Table 5) .
The IDU who were older than 29 years, who had injected drugs for 10 or more years, who had borrowed syringes, and who had engaged in prostitution during the time periods before seroconversion had somewhat higher HIV seroincidence rates. However, these differences were not statistically significant. Of the 44 IDU who had received MMT during the study period (total follow-up time 46 person-years), none seroconverted compared to nine seroconversions among IDU not receiving MMT (total follow-up time 106 personyears, incidence rate 8.5) (P = 0.01).
DISCUSSION
In this study, syringe sharing in prison was strongly and independently associated with HIV infection. This provides further evidence that prisons are places where IDU who continue to inject are at high risk of HIV infection. 8, 9, 12, 26 There have been case reports of HBV and HCV transmission among incarcerated IDU. 12, 27 To our knowledge, however, this is the first large-scale study which identified syringe sharing in prison as an important determinant of HBV and HCV infection. In prisons, syringes tend to be used by many individuals. Thus, the risk of syringe contamination by these viruses is much higher in prison than outside where syringes are usually shared with only one or two other people. 9 Moreover, HIV, HBV, and HCV seroprevalences are particularly high among imprisoned IDU.
Our study corroborates previous findings that injecting drug use and syringe sharing in prisons are common among IDU. 12, 28, 29 In our study, 22% of the participants had ever shared syringes while in prison, and 7% had done so in the previous 6 months. This has important implications for prevention where a pragmatic approach is necessary. In most prisons, it is not possible to entirely prevent the injection use of illicit drugs. However, injection with contaminated equipment could be substantially reduced if sterile injection equipment was available. An alternative would be to provide disinfectants for cleaning used syringes and needles. However, disinfectants such as household bleach have been shown to have only limited effectiveness against HIV and other viruses under field conditions. 30 In a few countries, pilot projects which provide sterile injection equipment in prisons (via syringe vending machines) were implemented. The first project was carried out in a Swiss prison for females. 31 The evaluation of the project did not show any adverse effects such as increased injecting drug use, or offences against prison personnel. However, much larger longitudinal studies including control groups are necessary to be able to show any true protective effect of the syringe vending machines against parenterally transmitted diseases. In Germany, similar projects started in 1996 in two places (Hamburg, and in Lower Saxony), another will start in Berlin in 1997. The good opportunities in prisons to contact large number of IDU over longer periods should not be missed. There should be specific activities to repeatedly counsel imprisoned IDU on the risks of parenterally transmitted infections. Although a substantial proportion of incarcerated IDU already have serological evidence of previous HBV infection, prisons are good places to implement hepatitis B vaccination programmes for HBV-seronegative individuals because the complete vaccination scheme can be administered to many IDU.
Some limitations of our study should be considered. In the cross-sectional study, we identified a history of syringe sharing as an important determinant of HBV, HCV, and HIV infection. However, due to the study design there is no proof that these associations are causal. Moreover, a history of syringe sharing inside prisons may only be a marker of risk behaviour outside prisons and not an independent risk factor per se. In fact, syringe sharing in prison was significantly associated with variables concerning risk behaviour outside prisons such as syringe sharing or prostitution. However, after adjusting for such variables in logistic regression, a history of syringe sharing in prison remained strongly associated with the three viral infections. Although information on the relevant injection and sexual risk behaviours was obtained in detail we cannot rule out residual confounding by behavioural characteristics on which no or only insufficient information has been collected. However, the adjusted HBV, HCV, and HIV prevalence odds ratios for frequent syringe sharing in prison were relatively high. This makes it unlikely that they are entirely explained by residual confounding.
Selection bias may arise in nonexperimental study designs. However, because of the multisite sampling strategy, and the high response rates among the eligible IDU in the cross-sectional study it is unlikely that the findings solely are due to selection bias. Nevertheless, the results should be corroborated in large longitudinal studies including follow-up of imprisoned IDU.
The HIV incidence rate of 5.9 per 100 person-years in the longitudinal study appears to be relatively high in a city where a wide range of specific prevention measures for IDU already exist and where sterile injection equipment is readily available outside prisons. However, similar or even higher HIV incidence rates of 6.3, and 9.5 per 100 person-years have been reported from the North-Italian and the Amsterdam cohort in the first year of follow-up. 16, 17 It is noteworthy that eight of the nine HIV seroconversions in our study were diagnosed at the first follow-up visit. Thus, some of the seroconverters may have acquired HIV infection already before they entered the study. Moreover, the incidence rate in our study may overestimate the true incidence among IDU in Berlin, because IDU with definite risk behaviour may have returned for follow-up visits in order to check out whether their recent risk behaviour actually resulted in HIV infection. Nevertheless, our results clearly indicate that new infections continue to occur even in areas where IDU have good access to sterile injection equipment.
Four of the nine seroconverters had borrowed syringes while in prison during the year before seroconversion, compared to 12 of the 146 nonconverters. It is possible that the four seroconverters had acquired HIV in prison. However, because of the relatively short follow-up periods and the small number of HIV seroconversions it was not possible to identify independent risk factors of HIV seroconversion. The univariate analysis suggests that MMT may be effective against HIV infections. This is in accordance with other studies. 32, 33 It also lends support to a previous cross-sectional study, where we found a protective effect of MMT against the current borrowing of syringes. 22 Since 1988, IDU have had easier access to MMT. However, for HIVnegative IDU it is still relatively difficult to obtain MMT. To improve the prevention of parenterally transmitted diseases MMT should not be restricted to HIVinfected IDU.
The data provide further evidence that MMT may reduce HIV incidence among IDU. However, since the individuals were not randomized to receiving or not receiving methadone, the characteristics that led them to seek or be accepted into methadone maintenance (e.g. risk awareness, social status, self-efficacy) may also have influenced the likelihood that they would engage in high-risk injection practices.
The HBV and HCV incidence rates in our study were higher than HIV incidence. These findings have to be interpreted with caution because of the small numbers of individuals who were HBV-and HCV-seronegative at baseline. However, the findings are in accordance with the much higher HBV and HCV seroprevalences as compared to the HIV seroprevalence among IDU in many cities, and the fact that HBV and HCV are more easily transmitted by needle-stick exposure than HIV. 34, 35 Longitudinal studies from Amsterdam, Geneva, and Victoria (Australia) have also reported higher HBV and HCV incidences than HIV incidence. 18, 21 In previous prevention programmes for IDU, HBV and HCV infection have been somewhat neglected. Efforts to reduce transmission of these viruses among IDU should be intensified. For example, specific hepatitis B vaccination programmes should be implemented for IDU, and prevention campaigns should specifically address the risk of HCV infection.
